We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+79.02%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.39B
AUM Growth
+$281M
Cap. Flow
-$93.3M
Cap. Flow %
-6.73%
Top 10 Hldgs %
66.46%
Holding
81
New
10
Increased
14
Reduced
17
Closed
22

Top Buys

Rank Stock Value
1
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$37.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$27M
3
MRK icon
Merck
MRK
+$20.7M
4
BIIB icon
Biogen
BIIB
+$17.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$16.9M

Top Sells

Rank Stock Value
1
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$46.7M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$26.2M
3
BMY icon
Bristol-Myers Squibb
BMY
+$24.3M
4
AGN
Allergan plc
AGN
+$22.6M
5
AMGN icon
Amgen
AMGN
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 94.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$154M 11.13%
1,109,874
– –
NXTC icon
2
NextCure
NXTC
$17.3M
$151M 10.85%
222,655
+12,500
+6% +$6.27M
KRTX
3
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$142M 10.24%
1,885,602
+156,250
+9% +$6.84M
AMRN
4
Amarin Corp
AMRN
$284M
$112M 8.05%
260,415
– –
NTRA icon
5
Natera
NTRA
$37.5B
$104M 7.53%
3,100,560
– –
PRNB
6
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$77.6M 5.6%
1,417,258
– –
YMAB
7
DELISTED
Y-mAbs Therapeutics
YMAB
$68.6M 4.94%
2,194,278
+90,000
+4% +$2.66M
GRTX
8
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$40.6M 2.93%
+3,083,712
New +$37.6M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$11.5B
$37.4M 2.69%
441,872
+356,976
+420% +$27M
CHRS icon
10
Coherus Oncology
CHRS
$217M
$34.8M 2.51%
1,933,221
– –
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$121B
$30.5M 2.2%
139,164
+17,474
+14% +$3.54M
MRUS
12
DELISTED
Merus
MRUS
$27.6M 1.99%
1,961,039
– –
PTCT icon
13
PTC Therapeutics
PTCT
$6.37B
$24.8M 1.79%
517,092
+229,847
+80% +$9.77M
MRK icon
14
Merck
MRK
$324B
$21.9M 1.58%
+252,365
New +$20.7M
BIIB icon
15
Biogen
BIIB
$29.9B
$18.9M 1.36%
+63,711
New +$17.7M
REGN icon
16
Regeneron Pharmaceuticals
REGN
$68.8B
$18.8M 1.36%
+50,086
New +$16.9M
OBSV
17
DELISTED
ObsEva SA Ordinary Shares
OBSV
$18.1M 1.31%
4,749,623
– –
UTHR icon
18
United Therapeutics
UTHR
$26.3B
$16.6M 1.2%
188,645
-5,369
-3% -$472K
CCXI
19
DELISTED
ChemoCentryx, Inc.
CCXI
$14.9M 1.07%
+376,944
New +$6.62M
MYOK
20
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$14.3M 1.03%
195,871
+81,945
+72% +$4.97M
MRTX
21
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$14M 1.01%
108,383
+77,583
+252% +$7.48M
NCNA
22
NuCana
NCNA
$5.37M
$13.8M 1%
453
– –
MGNX icon
23
MacroGenics
MGNX
$235M
$12.8M 0.92%
1,173,882
+592,328
+102% +$5.86M
FATE icon
24
Fate Therapeutics
FATE
$281M
$12.4M 0.9%
635,143
+253,543
+66% +$4.03M
ALNY icon
25
CALL
Alnylam Pharmaceuticals
ALNY
$36.3B
$11.5M 0.83%
+100,000
New +$9.97M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2019 Portfolio in Review

As of Q4 2019, Sofinnova Investments held 81 positions worth $1.39B, up 25% from $1.11B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Sofinnova Investments withdrew a net $93.3M in Q4 2019, closing 22 positions and reducing 17 holdings. Its most notable exit was Spark Therapeutics, Inc. Common Stock, an estimated $46.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 88% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Galera Therapeutics, Inc. Common Stock worth $40.6M.

  • Sofinnova Investments's largest Q4 2019 buy was Galera Therapeutics, Inc. Common Stock: 3,083,712 shares worth $40.6M.
  • Sofinnova Investments added most to BioMarin Pharmaceuticals in Q4 2019, an estimated $27M increase.
  • Sofinnova Investments's biggest Q4 2019 reduction was Acceleron Pharma, cutting an estimated $11.9M.
  • Sofinnova Investments fully exited Spark Therapeutics, Inc. Common Stock in Q4 2019, selling an estimated $46.7M.
  • Sofinnova Investments's ten largest holdings make up 66% of its $1.39B portfolio in Q4 2019.
  • Sofinnova Investments opened 10 new positions and closed 22 in Q4 2019.
  • Sofinnova Investments's portfolio value rose 25% quarter-over-quarter to $1.39B.

Based on Sofinnova Investments's 13F filing for Q4 2019, filed 14 Feb 2020.